Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03871725
Other study ID # Ye Tian carotid pilot
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 5, 2019
Est. completion date January 30, 2020

Study information

Verified date February 2021
Source First Affiliated Hospital of Harbin Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sonodynamic therapy (SDT) is a new treatment for carotid atherosclerotic plaque. The purpose of this study is to evaluate the safety and initial effectiveness of this technique.


Description:

Carotid atherosclerotic plaque is an important cause of ischemic stroke. Treatments for patients with carotid plaque include lifestyle changes, medical management(such as control of hyperlipidemia, hypertension, and diabetes) and carotid revascularization(carotid endarterectomy or carotid artery stenting). Studies have suggested that plaque morphology and composition are important determinants of plaque stability, using serial MR imaging of the carotid artery allowed observation of changes in plaque composition. Contrast enhanced ultrasound (CEUS) is a well accepted technique for detection of intraplaque neovascularization(IPN) in carotid atherosclerotic disease. The purpose of this trial is to evaluate the safety and initial effectiveness of SDT. The SDT can induce macrophage elimination and inhibit matrix degradation, which will promote plaque lipid depletion, inflammation level decrease and changes in other plaque tissue components, leading to plaque stabilization and reduction.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date January 30, 2020
Est. primary completion date January 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Age 18- 80 years - Carotid artery with 30%~70% stenosis by ultrasound and plaque thickness>2.5mm - Patients without transient ischemic attack, minor stroke or amaurosis fugax within 6 months - Patients' LDL-c level below 100 mg/dL(2.6mmol/L), well-controlled blood pressure(systolic BP<140 and diastolic BP<90 under resting conditions) and diabetes(HbA1c<7%) - Written informed consent Exclusion Criteria: - Non-atherosclerotic carotid artery stenosis - Contraindication to MRI( uses pacemaker, has metallic implants, claustrophobia) - Acute MI, acute coronary syndrome or stroke within 4 weeks prior to visit - Severe cerebral artery stenosis, atrial fibrillation or MRI detected thrombosis that would cause stroke - Previous significant adverse reaction to a statin - Systemic disorders such as hepatic, renal, hematologic, and malignant disease - Medical history that might limit the individual's ability to take trial treatments for the duration of the study - Allergic to DVDMS or sonovue - Diagnosis of porphyria - Pregnant women and nursing mothers - History of bilateral carotid endarterectomy or has immediate plans for carotid endarterectomy - Patient who is attending other clinical trial

Study Design


Intervention

Combination Product:
Sonodynamic therapy (SDT)
Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.

Locations

Country Name City State
China The First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital of Harbin Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in plaque LRNC volume, as assessed by MRI The changes in plaque lipid-rich necrotic core (LRNC) volume as assessed by MRI. Measured at Baseline, 1, 3 months
Secondary Change in plaque FT volume, as assessed by MRI The changes in plaque fibrous tissue(FT) volume as assessed by MRI. Measured at Baseline, 1, 3 months
Secondary Change in IPH volume, as assessed by MRI The changes in intraplaque hemorrhage (IPH) volume as assessed by MRI. Measured at Baseline, 1, 3 months
Secondary Change in calcification volume, as assessed by MRI The changes in calcification volume as assessed by MRI. Measured at Baseline, 1, 3 months
Secondary Change in the status of fibrous cap, as assessed by MRI The status of fibrous cap can be differentiated as thin/thick/ruptured assessed by MRI. Measured at Baseline, 1, 3 months
Secondary Change in plaque wall volume, as assessed by MRI The changes in plaque wall volume(mm3) as assessed by MRI Measured at Baseline, 1, 3 months
Secondary Change in MVE, as assessed by CEUS The changes in normalised maximal video-intensity enhancement (MVE) are calculated to quantify the density of IPN as assessed by CEUS. Measured at Baseline, 1, 3 months
Secondary Change in peak flow velocity, as assessed by doppler ultrasound The changes of the systolic and diastolic peak flow velocity of the affected segments by doppler ultrasound. Measured at Baseline, 1, 3 months
Secondary MACCE incidence of major adverse cardiovascular and cerebrovascular events(MACCE) Measured at Baseline, 1, 3 months
Secondary Incidence of adverse events Allergic to sunshine,hepatic or renal dysfunction,thyroid dysfunction Measured at Baseline, 1, 3 months
Secondary Lipid change To evaluate the change in lipid levels. Measured at Baseline, 1, 3 months
See also
  Status Clinical Trial Phase
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Withdrawn NCT03630835 - 99m Tc-ANNexin-V-128 Scintigraphy for the Identification of Complicated Carotid Atherosclerotic Plaques Phase 2/Phase 3
Completed NCT02722720 - Carotid Arteries Stenting Complications: Transradial Approach Versus Transfemoral N/A
Completed NCT01893489 - Visualization of Carotid Atherosclerosis by 68Ga-MSA Phase 1
Withdrawn NCT00861159 - RLIP76 in Human Serum in Adults With Rheumatologic Diseases N/A
Recruiting NCT01743404 - Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis Phase 2
Completed NCT00636766 - Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque N/A
Recruiting NCT06166121 - Study on Hyperlipidemia Combined With Carotid Atherosclerosis With ShenJu Granules N/A
Withdrawn NCT03382249 - Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With Carotid Atherosclerotic Plaques Phase 1/Phase 2
Recruiting NCT04679727 - The Carotid Artery Multi-modality Imaging Prognostic (CAMP) Study
Withdrawn NCT02995642 - Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation Phase 2
Suspended NCT01000181 - Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT N/A
Completed NCT00001368 - Potential Risk Factors for Stroke Phase 1
Recruiting NCT04537403 - PET Detection of CCR2 in Human Atherosclerosis Phase 1
Recruiting NCT05800821 - Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning
Completed NCT00147251 - Stop Atherosclerosis in Native Diabetics Study Phase 4
Completed NCT00147797 - Influence of Pravastatin on Carotid Artery Structure and Function in HIV-infected Patients Under Antiretroviral Therapy N/A
Completed NCT00180518 - ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial" Phase 2/Phase 3
Completed NCT05230576 - Intelligent Detection of Carotid Plaque and Its Stability Based on Deep Learning Dynamic Ultrasound Scanning
Terminated NCT03764306 - New Ischemic Cerebral Lesions After Endarterectomy vs. Stenting for the Treatment of Symptomatic Carotid Stenosis N/A